Asbt inhibitors in the treatment of renal diseases
US-2024207286-A1 · Jun 27, 2024 · US
US2022081461A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022081461-A1 |
| Application number | US-202117537612-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 30, 2021 |
| Priority date | Dec 19, 2017 |
| Publication date | Mar 17, 2022 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene L-proline monohydrate.
Opening claim text (preview).
What is claimed: 1 . An intermediate compound selected from the group consisting of: 2 . The intermediate compound of claim 1 , wherein the intermediate compound is:
Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins · CPC title
Carbocyclic radicals · CPC title
Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 · CPC title
the ring being unsaturated · CPC title
Acyclic or carbocyclic radicals, substituted by hetero rings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.